Clinical Trial Detail

NCT ID NCT01472016
Title Study of ABT-700 in Subjects With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie (prior sponsor, Abbott)
Indications

Advanced Solid Tumor

Therapies

Docetaxel

ABT-700

Cetuximab

Erlotinib

Fluorouracil + Irinotecan + Leucovorin

Age Groups: senior adult

No variant requirements are available.